Table 1.

Clinical and pathological characteristics of all patients

Clinical and pathological characteristicsa	N = 308b	%
Age, median (years)	57.98
Follow up, average (months)	109.89
Median	125
Histologyc
Invasive lobular	41	13.31
Invasive medullar	10	3.25
Invasive mucinous	3	0.97
No special type (NST)	161	52.27
DCIS with NST	78	25.33
Unknown	15	4.87
ER status
Positive	248	80.52
Negative	58	18.83
Unknown	2	0.65
PR status
Positive	178	57.79
Negative	128	41.56
Unknown	2	0.65
HER2 status
Positive	35	11.36
Negative	271	87.99
Unknown	2	0.65
Molecular subtype
Luminal A (Ki-67 ≤ 14%)	170	55.19
Luminal B (Ki-67 > 14%)	63	20.45
HER2 positive luminal	27	8.77
HER2 positive non luminal	8	2.60
Triple negative	38	12.34
Unknown	2	0.65
Grade
I	15	4.87
II	102	33.12
III	45	14.61
Unknown	146	47.40
Tumor size
pT1	191	62.01
pT2	87	28.25
pT3	4	1.30
pT4	12	3.90
Unknown	14	4.55
Lymph node metastasis
Yes	126	40.91
No	163	52.92
Unknown	19	6.17
Local recurrenced
Yes	41	13.31
No	253	82.14
Unknown	14	4.55
Distant metastasese
Yes	60	19.48
No	234	75.97
Unknown	14	4.55

^aAll information given refer to the primary tumor

^b5 of 303 patients are bilateral primary BC, so we deal with the tumor as individual one (n = 308)

^cNST include the formerly called “Invasive ductal” and “other” types

^dLocal recurrence has been detected during the follow-up of 40 patients (1 of them are bilateral BC, so n = 41)

^eDistant metastasis has been detected during the follow-up of 58 patients (2 of them are bilateral BC, so n = 60)